Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels

BMRN
BioMarin Pharmaceuticals Inc
stock NASDAQ

Market Open
Jul 10, 2025 3:48:05 PM EDT
58.78USD-1.483%(-0.89)1,051,807
56.00Bid   58.80Ask   2.80Spread
Pre-market
Jul 10, 2025 9:19:30 AM EDT
60.04USD+0.620%(+0.37)1,139
After-hours
Jul 9, 2025 4:00:30 PM EDT
59.67USD+0.008%(0.00)0
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 28, 2022
09:50PM EST  Swick & Foti, LLC Continues to Investigate the Officers and Directors of BioMarin Pharmaceutical Inc. - BMRN   PR Newswire
Jan 14, 2022
11:17PM EST  Swick & Foti, LLC Investigates the Officers and Directors of BioMarin Pharmaceutical Inc. - BMRN   PR Newswire
Jan 10, 2022
03:50PM EST  Biomarin Pharmaceutical shares were trading higher after the company said its hemophilia gene therapy met its efficacy endpoints.   Benzinga
06:29AM EST  BioMarin's Hemophilia Gene Therapy Meets Efficacy Endpoints At Two Year Analysis   Benzinga
Jan 9, 2022
09:44PM EST  BioMarin Pharmaceutical Inc. (BMRN) announced stable and durable annualized bleed control in phase 3 GENEr8-1 study of valoctocogene roxaparvovec in adults with Severe Hemophilia A. The 134-participant study met all primary and secondary efficacy endpoints at two year analysis.   RTTNews
03:14PM EST  Phase 3 Gene Therapy Study in Adults with Severe Hemophilia A; 134-Participant Study Met All Primary and Secondary Efficacy Endpoints at Two Year Analysis   PR Newswire
Jan 4, 2022
06:01AM EST  BioMarin to Participate in Two Virtual Investor Conferences in January   PR Newswire
Dec 20, 2021
11:51AM EST  BioMarin Granted FDA Orphan Designation For Treatment Of Hereditary Angioedema   Benzinga
Dec 19, 2021
09:36PM EST  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with   GlobeNewswire Inc
Dec 16, 2021
04:06PM EST  BioMarin Pharma Reports Multi-Year Strategic Collab For Discovery, Development, Commercialization Of Adeno-Associated Virus Gene Therapies To Treat Genetic Cardivascular Disesases   Benzinga
04:06PM EST  BioMarin and Skyline Therapeutics Announce Strategic Collaboration to Develop   PR Newswire
Dec 15, 2021
04:07PM EST  BioMarin Appoints Mark Alles To Board Of Directors   RTTNews
04:06PM EST  BioMarin Appoints Former CEO of Celgene Corporation, Mark Alles, to Board of   PR Newswire
Dec 7, 2021
05:14PM EST  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with   GlobeNewswire Inc
Nov 30, 2021
08:45AM EST  BioMarin to Hold Virtual R&D Day at 11:00am ET Today   PR Newswire
Nov 29, 2021
08:31AM EST  BioMarin to Participate in Two Upcoming Virtual Investor Conferences   PR Newswire
Nov 24, 2021
03:34PM EST  Levi & Korsinsky, LLP, Researching Possible Securities Law Violations -   PR Newswire
Nov 22, 2021
11:10AM EST  Where Biomarin Pharmaceutical Stands With Analysts   Benzinga
10:06AM EST  Benzinga's Top Ratings Upgrades, Downgrades For November 22, 2021   Benzinga
09:30AM EST  Credit Suisse Maintains Outperform on Biomarin Pharmaceutical, Raises Price Target to $105   Benzinga
08:25AM EST  Morgan Stanley Maintains Equal-Weight on Biomarin Pharmaceutical, Raises Price Target to $90   Benzinga
07:30AM EST  10 Biggest Price Target Changes For Monday   Benzinga
06:16AM EST  William Blair Upgrades Biomarin Pharmaceutical to Outperform   Benzinga
04:42AM EST  SVB Leerink Maintains Outperform on Biomarin Pharmaceutical, Raises Price Target to $115   Benzinga
Nov 19, 2021
05:25PM EST  BioMarin Pharmaceutical Inc. (BMRN) Friday said that the U.S. Food and Drug Administration has granted accelerated approval to Voxzogo, the first drug approved by the FDA to improve growth in children with most common form of dwarfism.   RTTNews
01:49PM EST  BioMarin Says Average Net Price Per Patient Per Year Is Estimated At $240,000 For Voxzogo, Says US Wholesale Acquisition Cost, Or List Price, Per Vial Is $899 For Voxzogo   Benzinga
10:44AM EST  BioMarin Receives FDA Approval For VOXZOGO   RTTNews
10:43AM EST  Indicated to Increase Linear Growth in Children with Achondroplasia Aged 5 and Up with Open Growth Plates   PR Newswire
10:39AM EST  FDA Approves BioMarin's Vosoritide For Children With Most Common Form Of Dwarfism   Benzinga
Nov 15, 2021
11:09AM EST  Entos, BioMarin Report Deal For Product Candidates Incorporating Entos' Fusogenix Drug Delivery Platform   Benzinga
10:45AM EST  SVB Leerink Maintains Outperform on Biomarin Pharmaceutical, Raises Price Target to $112   Benzinga
10:37AM EST  The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More   Benzinga
08:32AM EST  Entos And BioMarin Enter Agreement To See Entos Apply Its Fusogenix Nucleic Acid Delivery Technology   RTTNews
08:30AM EST  Entos and BioMarin Enter into Agreement for Product Candidates Incorporating   PR Newswire
Nov 9, 2021
03:23PM EST  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with   GlobeNewswire Inc
Oct 28, 2021
05:50PM EDT  17:50 Thursday, October 28, 2021Wedbush (RTTNews) - Wedbush Reiterates Biomarin Pharmaceutical Inc. (BMRN) At Outperform With $152 Price Target   RTTNews
09:16AM EDT  Credit Suisse Maintains Outperform on Biomarin Pharmaceutical, Lowers Price Target to $100   Benzinga
07:14AM EDT  BioMarin's Q3 Net Income Hit By Lower Product Sales   Benzinga
Oct 27, 2021
06:14PM EDT  Biomarin Pharmaceutical: Q3 Earnings Insights   Benzinga
05:04PM EDT  BioMarin Lifts FY Guidance Driven By Product Demand   RTTNews
04:49PM EDT  BioMarin Sees FY21 Sales $1.82B-$1.88B vs $1.85B Est.   Benzinga
04:48PM EDT  Biomarin Pharmaceutical Q3 EPS $(0.20) Beats $(0.25) Estimate, Sales $408.70M Miss $435.32M Estimate   Benzinga
04:15PM EDT  BioMarin Q3 Loss/share $0.29 Vs. Profit $4.01 Year Ago   RTTNews
04:06PM EDT  BioMarin Announces Third Quarter 2021 Financial Results and Corporate Updates   PR Newswire
03:43AM EDT  Earnings Scheduled For October 27, 2021   Benzinga
Oct 25, 2021
08:34PM EDT  /C O R R E C T I O N -- Pomerantz LLP/   PR Newswire
03:49PM EDT  Gainey McKenna & Egleston Announces A ClassAction   GlobeNewswire Inc
08:31AM EDT  BioMarin to Participate in Four Upcoming Virtual Investor Conferences   PR Newswire
Oct 24, 2021
11:45AM EDT  The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More   Benzinga
Oct 23, 2021
12:00AM EDT  Pomerantz Law Firm Announces the Filing of a Class Action Against BioMarin   PR Newswire
Oct 16, 2021
04:15PM EDT  Barron's Latest Picks And Pans: Amazon, Apple, Chevron, Citigroup, Dell And More   Benzinga
Oct 12, 2021
08:31AM EDT  BioMarin to Host Third Quarter 2021 Financial Results Conference Call and   PR Newswire
Oct 4, 2021
08:33AM EDT  BioMarin Names Harold Bernstein SVP, Chief Medical Officer And Head Of Clinical Development   RTTNews
08:31AM EDT  BioMarin Hires Industry Veterans to Fill Key Roles in R&D and Technical   PR Newswire
Sep 9, 2021
11:05AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2021   Benzinga
06:51AM EDT  Stifel Upgrades Biomarin Pharmaceutical to Buy, Raises Price Target to $96   Benzinga
Sep 7, 2021
09:54AM EDT  Price To Earnings Ratio Insights For Biomarin Pharmaceutical   Benzinga
08:51AM EDT  Benzinga Pro's Top 5 Stocks To Watch For Tuesday, Sept. 7, 2021: PLAY, SPOT, MTCH, BMRN, RNXT   Benzinga
06:11AM EDT  FDA Slaps Clinical Hold on BioMarin's Gene Therapy For Genetic Metabolism Disorder   Benzinga
Sep 6, 2021
02:27AM EDT  Based on interim safety findings from a pre-clinical, non-GLP pharmacology study, FDA has placed a clinical hold on the BMN 307 Phearless Phase 1/2 study, BioMarin Pharmaceutical Inc. (BMRN) said. The study is evaluating BMN 307, an investigational AAV5-phenylalanine hydroxylase gene therapy in adults with phenylketonuria.   RTTNews
02:06AM EDT  BioMarin : FDA Places Clinical Hold On BMN 307 Phearless Phase 1/2 Gene Therapy Study In Adults With Phenylketonuria   RTTNews
02:01AM EDT  U.S. FDA Placed a Clinical Hold on BMN 307 Phearless Phase 1/2 Gene Therapy   PR Newswire
Aug 30, 2021
07:40AM EDT  07:40 Monday, August 30, 2021Wedbush (RTTNews) - Wedbush Reiterates Biomarin Pharmaceutical Inc. (BMRN) At Outperform With $152 Up From $141 Price Target   RTTNews
Aug 27, 2021
11:50AM EDT  Drug For Short-Limbed Dwarfism From Biomarin Wins European Approval   Benzinga
09:17AM EDT  BioMarin Pharmaceutical Inc. (BMRN) said the European Commission has granted marketing authorization for VOXZOGO (vosoritide). It is the first medicine to be approved to treat children with achondroplasia in Europe. Achondroplasia is the most common cause of dwarfism.   RTTNews
09:04AM EDT  EU Oks BioMarin's VOXZOGO For Treatment Of Children With Achondroplasia From Age 2 Until Growth Plates Close   RTTNews
09:02AM EDT  European Commission Approves BioMarin's VOXZOGO (vosoritide) For Treatment Of Children With Achondroplasia From Age 2 Until Growth Plates Close   Benzinga
09:01AM EDT  Treatment of Children with Achondroplasia from Age 2 Until Growth Plates Close   PR Newswire
Aug 25, 2021
08:31AM EDT  BioMarin to Participate in Three Upcoming Virtual Investor Conferences   PR Newswire
Jul 29, 2021
10:52AM EDT  RBC Capital Maintains Sector Perform on Biomarin Pharmaceutical, Raises Price Target to $88   Benzinga
07:13AM EDT  BioMarin Bounces Back With Solid Q2 Earnings, Nudges Up 2021 Guidance   Benzinga
Jul 28, 2021
04:51PM EDT  Biomarin Pharmaceutical: Q2 Earnings Insights   Benzinga
04:17PM EDT  BioMarin Raises FY21 Total Revenue Guidance From $1.75B-$1.85B To $1.79B-$1.88B vs $1.82B Est.   Benzinga
04:10PM EDT  BioMarin Q2 EPS $0.07 Vs. Loss $0.16 Year Ago   RTTNews
04:05PM EDT  Biomarin Pharmaceutical Q2 EPS $0.07 Beats $(0.11) Estimate, Sales $501.70M Beat $448.79M Estimate   Benzinga
04:03PM EDT  BioMarin Announces Second Quarter 2021 Financial Results and Corporate Updates   PR Newswire
07:33AM EDT  The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal   Benzinga
04:27AM EDT  Earnings Scheduled For July 28, 2021   Benzinga
Jul 25, 2021
10:05AM EDT  The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More   Benzinga
Jul 22, 2021
09:27AM EDT  UPDATE: Lixte Says 'vosoritide (BioMarin), was even more effective than vosorotide alone in stimulating bone length and cartilage area in a mouse model of the most common form of dwarfism'   Benzinga
08:30AM EDT  08:29 Thursday, July 22, 2021Wedbush (RTTNews) - Wedbush Reiterates Biomarin Pharmaceutical Inc. (BMRN) At Outperform With $141 Price Target   RTTNews
Jul 21, 2021
12:03PM EDT  BioMarin Shares 5-Year Data From Open-Label Trial Of Hemophilia Gene Therapy   Benzinga
10:21AM EDT  BioMarin Pharmaceutical Inc.'s (BMRN) long-term clinical data from the ongoing phase 1/2 study of valoctocogene roxaparvovec in adults with Severe Hemophilia A demonstrated continued, durable clinical benefit.   RTTNews
10:04AM EDT  BioMarin Announces Data For Valoctocogene Roxaparvovec, Gene Therapy Treatment For Adults With Severe Hemophilia A   RTTNews
10:03AM EDT  Biomarin Pharmaceutical Announces Oral Presentation At International Society On Thrombosis And Haemostasis 2021 Virtual Congress   Benzinga
10:01AM EDT  Haemostasis (ISTH) 2021 Virtual Congress with 5 Years of Clinical Data from Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec in Adults with Severe Hemophilia A, Demonstrating Continued, Durable Clinical Benefit   PR Newswire
Jul 19, 2021
01:37PM EDT  BioMarin Pharmaceutical Inc. (BMRN) Monday announced new data for valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe hemophilia A, in its positive pivotal study, GENEr8-1, during an oral presentation at the International Society on Thrombosis and Haemostasis (ISTH) 2021 Virtual Congress.   RTTNews
01:16PM EDT  BioMarin Unveils News Data From Late-Stage Hemophilia A Gene Therapy Candidate   Benzinga
11:07AM EDT  BioMarin Phase 3 Trial On Valoctocogene Roxaparvovec Shows Superiority To Factor VIII Prophylaxis In Efficacy Endpoints   RTTNews
11:01AM EDT  BioMarin Announces Oral Presentation Of 1-Year Results From Phase 3 Pivotal Trial With Valoctocogene Roxaparvovec Gene Therapy In Adults With Sever Hemophilia A At International Society On Thrombosis A nd Haemostasis 2021 Virtual Congress   Benzinga
11:01AM EDT  Pivotal Trial with Valoctocogene Roxaparvovec Gene Therapy in Adults with Severe Hemophilia A at International Society on Thrombosis and Haemostasis (ISTH) 2021 Virtual Congress   PR Newswire
Jul 16, 2021
07:06AM EDT  07:05 Friday, July 16, 2021Wedbush (RTTNews) - Wedbush Reiterates Biomarin Pharmaceutical Inc. (BMRN) At Outperform With $141 Price Target   RTTNews
Jul 15, 2021
09:39AM EDT  BioMarin Expects EMA's CHMP Opinion In 1H 2022 For Its Hemophilia A Gene Therapy, FDA Resubmission In 2Q'22   Benzinga
09:00AM EDT  The European Medicines Agency or EMA validated BioMarin Pharmaceutical Inc.'s (BMRN) Marketing Authorization Application or MAA for its investigational gene therapy, valoctocogene roxaparvovec, for adults with severe hemophilia A, the company said in a statement.   RTTNews
08:37AM EDT  Application for Valoctocogene Roxaparvovec to Treat Severe Hemophilia A   PR Newswire
08:36AM EDT  AMMO Announces The European Medicines Agency Has Validated Co.'s Marketing Authorization Application For Valoctocogene Roxaparvovec   Benzinga
08:35AM EDT  EMA Validates BioMarin's MAA For Valoctocogene Roxaparvovec To Treat Severe Hemophilia A   RTTNews
Jul 14, 2021
08:32AM EDT  BioMarin to Host Second Quarter 2021 Financial Results Conference Call and   PR Newswire
Jul 2, 2021
09:07AM EDT  BioMarin Announces 12 Presentations At International Society On Thrombosis And Haemostasis (ISTH) 2021 Virtual Congress   Benzinga
09:07AM EDT  BioMarin Announces 12 Presentations On Thrombosis And Haemostasis   RTTNews
09:05AM EDT  BioMarin Announces 12 Presentations at the International Society on Thrombosis   PR Newswire
Jun 29, 2021
08:25AM EDT  08:25 Tuesday, June 29, 2021Wedbush (RTTNews) - Wedbush Reiterates Biomarin Pharmaceutical Inc. (BMRN) At Outperform With $141 Price Target   RTTNews
Jun 28, 2021
08:48AM EDT  Biotechnology company BioMarin Pharmaceutical Inc. (BMRN) announced Tuesday that it has resubmitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its investigational gene therapy, valoctocogene roxaparvovec, for adults with severe hemophilia A.   RTTNews
08:45AM EDT  BioMarin Resubmits Marketing Authorization Application To European Medicines Agency For Valoctocogene Roxaparvovec To Treat Severe Hemophilia A   Benzinga
08:33AM EDT  BioMarin Resubmits MAA To EU For Valoctocogene Roxaparvovec To Treat Severe Hemophilia A   RTTNews
08:31AM EDT  Medicines Agency for Valoctocogene Roxaparvovec to Treat Severe Hemophilia A   PR Newswire
Jun 25, 2021
01:30PM EDT  EMA's Advisory Committee Backs Approval Of BioMarin's Dwarfism Candidate   Benzinga
07:57AM EDT  BioMarin Gets Positive CHMP Opinion For Vosoritide To   RTTNews
07:32AM EDT  BioMarin Gets Positive CHMP Opinion In Europe For Vosoritide For Children With Achondroplasia   RTTNews
07:30AM EDT  BioMarin Receives Positive CHMP Opinion In Europe For Vosoritide For Treatment Of Children With Achondroplasia From Age 2 Until Growth Plates Close   Benzinga
07:29AM EDT  Treatment of Children with Achondroplasia from Age 2 Until Growth Plates Close   PR Newswire
Jun 15, 2021
08:31AM EDT  BioMarin to Participate in the Virtual BofA Securities 2021 Napa Biopharma   PR Newswire
May 27, 2021
08:31AM EDT  BioMarin to Participate in Two Upcoming Virtual Investor Conferences   PR Newswire
May 24, 2021
12:11PM EDT  EMA Grants BioMarin's Request For Speedy Review of Hemophilia A Gene Therapy   Benzinga
08:49AM EDT  The European Medicines Agency or EMA has granted its request for accelerated assessment of valoctocogene roxaparvovec, for adults with severe hemophilia A, BioMarin Pharmaceutical Inc. (BMRN) said in a statement.   RTTNews
08:38AM EDT  European Medicines Agency Grants BioMarin's Request For Accelerated Assessment Of Valoctocogene Roxaparvovec For Treatment Of Severe Hemophilia A   Benzinga
08:35AM EDT  BioMarin: EMA Grants Request For Accelerated Assessment Of Valoctocogene Roxaparvovec For Severe Hemophilia A   RTTNews
08:31AM EDT  European Medicines Agency Grants BioMarin's Request for Accelerated Assessment   PR Newswire
May 19, 2021
01:05PM EDT  Five-Year Data Of BioMarin's Hemophilia Gene Therapy Shows Sustained Benefit   Benzinga
10:27AM EDT  BioMarin Pharmaceutical Inc. (BMRN), in an update on phase 1/2 study of valoctocogene roxaparvovec, an investigational gene therapy treatment for adults with severe hemophilia A, said Wednesday that the safety profile of valoctocogene roxaparvovec in the study remains consistent with previously reported data with no delayed-onset treatment related adverse events.   RTTNews
08:40AM EDT  BioMarin Pharma Offers Update To Results From Open-Label Phase 1/2 Study Of Valoctocogene Roxaparvovec For Adults With Severe Hemophilia A   Benzinga
08:36AM EDT  BioMarin Updates On Results From Open-label Phase 1/2 Study Of Valoctocogene Roxaparvovec   RTTNews
08:31AM EDT  Study of Valoctocogene Roxaparvovec with the Longest Duration of Clinical Experience for a Gene Therapy in Hemophilia A   PR Newswire
May 18, 2021
08:31AM EDT  BioMarin to Participate in Two Upcoming Virtual Investor Conferences   PR Newswire
May 12, 2021
08:32AM EDT  BioMarin Announces 6 Presentations At American Society Of Gene And Cell Therapy Virtual 2021 Annual Meeting   Benzinga
08:31AM EDT  BioMarin Announces 6 Presentations at American Society of Gene and Cell Therapy   PR Newswire
May 3, 2021
08:31AM EDT  BioMarin to Participate in Two Upcoming Virtual Investor Conferences   PR Newswire
Apr 30, 2021
05:34PM EDT  17:33 Friday, April 30, 2021Wedbush (RTTNews) - Wedbush Reiterates Biomarin Pharmaceutical Inc. (BMRN) At Outperform With $139 Price Target   RTTNews
Apr 29, 2021
05:27PM EDT  Biomarin Pharmaceutical: Q1 Earnings Insights   Benzinga
05:27PM EDT  Biomarin Pharmaceutical Sees FY 2021 Revs $1.75B-$1.85B Vs $1.81B Est   Benzinga
04:32PM EDT  Biomarin Pharmaceutical Inc. (BMRN) revealed earnings for first quarter that declined from the same period last year.   RTTNews
04:21PM EDT  Biomarin Pharmaceutical Q1 GAAP EPS $0.09 Beats $(0.10) Estimate, Sales $486.00M Beat $446.45M Estimate; Reaffirms FY21 Guidance'   Benzinga
04:05PM EDT  BioMarin Q1 EPS $0.09 Vs. $0.44 Year Ago   RTTNews
04:03PM EDT  BioMarin Announces First Quarter 2021 Financial Results and Corporate Updates   PR Newswire
08:15AM EDT  The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx   Benzinga
04:10AM EDT  Earnings Scheduled For April 29, 2021   Benzinga
Apr 28, 2021
11:07AM EDT  Preview: Biomarin Pharmaceutical's Earnings   Benzinga
09:12AM EDT  The Allen Institute and BioMarin Pharmaceutical Inc. (BMRN) announced a collaboration today that will use technologies developed at the Allen Institute to create new gene therapies aimed at rare genetic diseases of the central nervous system. They did not disclose financial terms.   RTTNews
08:45AM EDT  Allen Institute and BioMarin Team Up To Develop Gene Therapies For Rare Brain Diseases   Benzinga
08:38AM EDT  Allen Institute, BioMarin Team Up To Develop Gene Therapies For Rare Brain Diseases   RTTNews
08:32AM EDT  Allen Institute and BioMarin Team Up To Develop Gene Therapies For Rare Brain   PR Newswire
Apr 24, 2021
09:24AM EDT  The Week Ahead In Biotech (April 25-May 1): FDA Decisions For Sol-Gel, Protalix Bio, Ardelyx   Benzinga
Apr 19, 2021
10:09AM EDT  Morgan Stanley Maintains Equal-Weight on Biomarin Pharmaceutical, Lowers Price Target to $82   Benzinga
Apr 15, 2021
08:44AM EDT  BioMarin Highlights Presentation Of Data At 2021 American College Of Medical Genetics And Genomics Annual Clinical Genetics Meeting   Benzinga
08:35AM EDT  BioMarin Announces New Data Demonstrating Commitment To Understanding Achondroplasia And Potential Treatment Choice   RTTNews
08:31AM EDT  Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting Demonstrating Commitment to Understanding Achondroplasia and Potential Treatment Choice   PR Newswire
Apr 13, 2021
08:31AM EDT  BioMarin to Host First Quarter 2021 Financial Results Conference Call and   PR Newswire
Mar 23, 2021
07:15AM EDT  07:15 Tuesday, March 23, 2021Wedbush (RTTNews) - Wedbush Reiterates Biomarin Pharmaceutical Inc. (BMRN) At Outperform With $139 Price Target   RTTNews
Mar 22, 2021
07:40AM EDT  07:40 Monday, March 22, 2021Wedbush (RTTNews) - Wedbush Reiterates Biomarin Pharmaceutical Inc. (BMRN) At Outperform With $139 Price Target   RTTNews
Mar 20, 2021
11:32AM EDT  BioMarin Presents Data From Open-label Long-term Extension Of Phase 3 Study Of 15 g/kg Dose Of Vosoritide At ENDO21   RTTNews
11:15AM EDT  Annual Meeting, with Data Demonstrating 2 Years of Treatment Benefit in Children with Achondroplasia Treated with Vosoritide   PR Newswire
Mar 19, 2021
10:50PM EDT  BIOMARIN INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of BioMarin Pharmaceutical Inc. - BMRN   Business Wire
Mar 8, 2021
12:05PM EST  BioMarin's Hemophilia Gene Therapy Scores RMAT Designation In US   Benzinga
08:47AM EST  Designation Granted to Valoctocogene Roxaparvovec, Investigational Gene Therapy for Hemophilia A   PR Newswire
08:47AM EST  BioMarin Says FDA Granted Regenerative Medicine Advanced Therapy Designation To Valoctocogene Roxaparvovec   RTTNews
08:34AM EST  BioMarin Announces FDA Regenerative Medicine Advanced Therapy Designation Granted to Valoctocogene Roxaparvovec, Investigational Gene Therapy for Hemophilia A   Benzinga
Mar 3, 2021
08:35AM EST  BioMarin Completes Enrollment In Phase2 Study Of Vosoritide For Treatment Of Infants, Young Children With Achondroplasia   RTTNews
08:33AM EST  BioMarin Reports Completion Of Full Enrollment In Phase 2 Study Of Vosoritide For Treatment Of Infants, Young Children With Achondroplasia   Benzinga
08:31AM EST  BioMarin Completes Full Enrollment in Phase 2 Study of Vosoritide for Treatment   PR Newswire
Mar 1, 2021
12:19PM EST  Canaccord Genuity Maintains Buy on Biomarin Pharmaceutical, Lowers Price Target to $91   Benzinga
10:45AM EST  Evercore ISI Group Upgrades Biomarin Pharmaceutical to Outperform, Raises Price Target to $100   Benzinga
Feb 26, 2021
10:50PM EST  Swick & Foti, LLC Investigates the Officers and Directors of BioMarin Pharmaceutical Inc. - BMRN   PR Newswire
Feb 25, 2021
04:25PM EST  BioMarin Announces Fourth Quarter and Record Full-year 2020 Financial Results   PR Newswire
04:25PM EST  Biomarin Pharmaceutical Inc. (BMRN) announced a profit for its fourth quarter that rose from the same period last year.   RTTNews
04:25PM EST  Biomarin Pharmaceutical Q4 EPS $0.12 Beats $(0.19) Estimate, Sales $452.10M Beat $440.23M Estimate   Benzinga
04:25PM EST  BioMarin Sees FY 2021 Non-GAAP Income $170M-$220M   Benzinga
04:25PM EST  BioMarin Sees FY 2021 Revs $1.75B-$1.85B Vs $1.91B Est   Benzinga
04:25PM EST  BioMarin Q4 EPS $0.12 Vs. $0.08 Year Ago   RTTNews
08:08AM EST  The Daily Biotech Pulse: Merck Goes Shopping, Decision Day For Sarepta, Pfizer, Moderna Unveil Vaccine Strategies For Coronavirus Variants   Benzinga
04:03AM EST  Earnings Scheduled For February 25, 2021   Benzinga
Feb 24, 2021
10:09AM EST  Biomarin Pharmaceutical's Earnings Outlook   Benzinga
08:31AM EST  BioMarin to Participate in Four Upcoming Virtual Investor Conferences   PR Newswire
Feb 18, 2021
04:02PM EST  BioMarin Appoints Maykin Ho To Board Of Directors   RTTNews
04:01PM EST  BioMarin Appoints Former Goldman Sachs Partner and Life Sciences Executive,   PR Newswire
Jan 28, 2021
09:03AM EST  BioMarin Earns Top Marks in Human Rights Campaign's 2021 Corporate Equality   PR Newswire
Jan 26, 2021
08:31AM EST  BioMarin to Host Fourth Quarter and Full Year 2020 Financial Results Conference   PR Newswire
Jan 15, 2021
10:51PM EST  BIOMARIN INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of BioMarin Pharmaceutical Inc. - BMRN   Business Wire
Jan 11, 2021
09:55AM EST  Shares of BioMarin Pharmaceutical Inc. (BMRN) are falling more than 8 percent or $7.67 in Monday's morning trade at $82.19.   RTTNews
Jan 10, 2021
10:06PM EST  BioMarin Pharmaceutical Inc. (BMRN) announced positive phase 3 gene therapy trial results in adults with Severe Hemophilia A. The study met all primary and secondary efficacy endpoints in one-year data set.   RTTNews
07:49PM EST  BioMarin Announces Positive Phase 3 Gene Therapy Trial Results In Adults With Severe Hemophilia A   RTTNews
06:45PM EST  Severe Hemophilia A; Study Met All Primary and Secondary Efficacy Endpoints in One-Year Data Set   PR Newswire
Jan 5, 2021
08:31AM EST  BioMarin to Participate in Two Upcoming Virtual Investor Conferences   PR Newswire
Dec 21, 2020
09:19AM EST  BioMarin Pharmaceutical Inc. (BMRN) said that children in the open-label long-term extension of the phase 3 study of vosoritide maintained an increase in annual growth velocity through the second year of continuous treatment. It is an investigational, once daily injection analog of C-type Natriuretic Peptide.   RTTNews
08:33AM EST  BioMarin :Children Treated With Vosoritide Show Cumulative Height Gain Of 3.52 Cm At Year 2 Vs. Untreated Children   RTTNews
08:30AM EST  BioMarin Announces Benefit Maintained For Over Two Years In Children with Achondroplasia Treated With Vosoritide In Phase 3 Extension Study   Benzinga
08:29AM EST  BioMarin Announces Benefit Maintained for Over Two Years in Children with   PR Newswire
Dec 14, 2020
08:54AM EST  BioMarin Pharmaceuticals, Citrix Systems, Expedia Group, Liberty Global, Take-Two Interactive Software, Ulta Beauty Shares Quiet; Cos Removed From Nasdaq-100 Index On Friday   Benzinga
Dec 12, 2020
04:43PM EST  Nasdaq-100's Annual Reconstitution: Expedia and Citrix Out, Peloton and Marvell Technology In   Benzinga
Dec 1, 2020
08:31AM EST  BioMarin to Participate in Two Upcoming Virtual Investor Conferences   PR Newswire
Nov 24, 2020
10:00AM EST  BMRN Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds   GlobeNewswire Inc
Nov 23, 2020
10:51PM EST  Swick & Foti, LLC Remind Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against BioMarin Pharmaceutical Inc. - BMRN   PR Newswire
12:00PM EST  BMRN FINAL DEADLINE NOTICE: ROSEN, GLOBAL INVESTOR COUNSEL,   GlobeNewswire Inc
12:00PM EST  Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.   GlobeNewswire Inc
11:00AM EST  The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.   GlobeNewswire Inc
Nov 22, 2020
10:50PM EST  BIOMARIN 48 HOUR DEADLINE ALERT: ClaimsFiler Reminds Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against BioMarin Pharmaceutical Inc. - BMRN   Business Wire
Nov 20, 2020
10:50PM EST  BIOMARIN 96 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against BioMarin Pharmaceutical Inc. - BMRN   Business Wire
08:00AM EST  Investors with losses are encouraged to contact the firm before November 24, 2020; click here to submit trade information   GlobeNewswire Inc
Nov 19, 2020
12:30PM EST  Glancy Prongay & Murray LLP (GPM) reminds investors of the upcomingNovember 24, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired BioMarin Pharmaceuticals, Inc. (BioMarin or the Company) (NASDAQ: BMRN) securities between February 28, 2020 and August 18, 2020, inclusive (the Class Period).   GlobeNewswire Inc
11:08AM EST  Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) from February 28, 2020 through August 18, 2020, inclusive (the Class Period). The lawsuit seeks to recover damages for BioMarin Pharmaceutical Inc. investors under the federal securities laws.   GlobeNewswire Inc
11:00AM EST  BMRN Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds BioMarin Pharmaceutical Inc. Shareholders of Class Action and Lead Plaintiff Deadline: November 24, 2020   Business Wire
Nov 18, 2020
11:18PM EST  of Important November 24 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm - BMRN   PR Newswire
10:50PM EST  Kahn Swick & Foti, LLC (KSF) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits:   GlobeNewswire Inc
11:00AM EST  GLNG & BMRN Deadlines: Bronstein, Gewirtz & Grossman LLC Reminds   GlobeNewswire Inc
Nov 17, 2020
11:45AM EST  The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.   GlobeNewswire Inc
08:30AM EST  BioMarin Pharmaceutical And Deep Genomics Enter Preclinical Collaboration   RTTNews
08:30AM EST  BioMarin And Deep Genomics To Collaborate On Advancing Programs Identified Using Artificial Intelligence; Collaboration Will Use Genomics' AI Workbench To 'identify oligonucleotide drug candidates in four rare disease indications with high unmet need'   Benzinga
08:29AM EST  BioMarin and Deep Genomics to Collaborate on Advancing Programs Identified   PR Newswire
Nov 16, 2020
11:08AM EST  IMMINENT SHAREHOLDER DEADLINE: BioMarin Pharmaceutical, Inc. Sued   GlobeNewswire Inc
11:00AM EST  Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.   GlobeNewswire Inc
Nov 13, 2020
09:57AM EST  Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) from February 28, 2020 through August 18, 2020. If you wish to serve as lead plaintiff, you must move the Court before the NOVEMBER 24, 2020 DEADLINE.   GlobeNewswire Inc
Nov 12, 2020
03:56PM EST  Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) from February 28, 2020 through August 18, 2020, inclusive (the Class Period). The lawsuit seeks to recover damages for BioMarin Pharmaceutical Inc. investors under the federal securities laws.   GlobeNewswire Inc
08:31AM EST  BioMarin to Participate in Three Upcoming Virtual Investor Conferences   PR Newswire
Nov 11, 2020
10:50PM EST  ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits:   GlobeNewswire Inc
03:00PM EST  Bragar Eagel & Squire, P.C. Reminds Investors That Class Action   GlobeNewswire Inc
Nov 9, 2020
11:00AM EST  The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.   GlobeNewswire Inc
08:34AM EST  BioMarin Expands Vosoritide Clinical Program; Enrolls First Child In Phase 2 Study For Children With Achondroplasia   RTTNews
08:31AM EST  BioMarin Expands Vosoritide Clinical Program   PR Newswire
Nov 8, 2020
01:53AM EST  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with   GlobeNewswire Inc
Nov 7, 2020
01:50PM EST  ROSEN, RECOGNIZED INVESTOR COUNSEL, Reminds BioMarin   GlobeNewswire Inc
Nov 6, 2020
10:50PM EST  ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits:   GlobeNewswire Inc
11:30AM EST  Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.   GlobeNewswire Inc
09:52AM EST  Biomarin Pharmaceuticals shares are trading lower after the company reported Q3 earnings results.   Benzinga
08:48AM EST  SVB Leerink Reiterates Outperform on Biomarin Pharmaceutical, Lowers Price Target to $108   Benzinga
Nov 5, 2020
05:15PM EST  Biomarin Sees FY20 Sales $1.85B-$1.95B vs $1.86B Est.   Benzinga
05:14PM EST  Biomarin Pharmaceutical Q3 EPS $4.01 May Not Compare To $1.29 Estimate, Sales $476.80M Beat $454.64M Estimate   Benzinga
04:14PM EST  Biomarin Pharmaceutical Inc. (BMRN) released a profit for its third quarter that increased from last year.   RTTNews
04:08PM EST  BioMarin Q3 EPS $4.01 Vs. $0.30 Year Ago   RTTNews
04:06PM EST  BioMarin Announces Third Quarter 2020 Total Revenues of $477 Million   PR Newswire
03:57PM EST  Notable Earnings Watchlist For Thursday, Nov. 5, 2020 After Market Close: NLOK, TTWO, Z, SYNA, GPRO, DBX, NWS, PTON, MCHP, MNST, UBER, YELP, WLL, WYNN, SQ, ROKU, BKNG, BMRN, CHMA, CHUY, AIG, GRPN, FLS, FLT, IAC, EA, ENDP   Benzinga
04:34AM EST  Earnings Scheduled For November 5, 2020   Benzinga
Nov 4, 2020
04:00PM EST  Bragar Eagel & Squire, P.C. Reminds Investors That Class Action   GlobeNewswire Inc
02:46PM EST  Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) from February 28, 2020 through August 18, 2020, inclusive (the Class Period). The lawsuit seeks to recover damages for BioMarin Pharmaceutical Inc. investors under the federal securities laws.   GlobeNewswire Inc
08:31AM EST  BioMarin to Participate in the Credit Suisse 29th Annual Virtual Healthcare   PR Newswire
Nov 3, 2020
11:45AM EST  The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.   GlobeNewswire Inc
07:38AM EST  The Daily Biotech Pulse: Aurinia Pulls The Plug On Dry Eye Disease Study, Karyopharm's Positive Readout, Emergency Use Authorization For OraSure   Benzinga
Nov 2, 2020
09:10PM EST  FDA Accepts BioMarin's NDA For Vosoritide To Treat Children With Achondroplasia; PDUFA Action Date Aug. 20, 2021   RTTNews
08:56PM EST  Food and Drug Administration Accepts BioMarin's New Drug Application for   PR Newswire
02:17PM EST  Hagens Berman updates investors in the following publicly-traded companies and urges investors who have suffered significant losses to contact the firm. Further details about the cases can be found at the links provided.   GlobeNewswire Inc
Oct 30, 2020
10:50PM EDT  Kahn Swick & Foti, LLC (KSF) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits:   GlobeNewswire Inc
07:45PM EDT  of Important November 24 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact Firm - BMRN   PR Newswire
Oct 28, 2020
08:00AM EDT  SHAREHOLDER ALERT: BioMarin Pharmaceutical, Inc. Sued for   GlobeNewswire Inc
Oct 27, 2020
12:00PM EDT  The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.   GlobeNewswire Inc
11:00AM EDT  Glancy Prongay & Murray LLP (GPM) reminds investors of the upcomingNovember 24, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired BioMarin Pharmaceuticals, Inc. (BioMarin or the Company) (NASDAQ: BMRN) securities between February 28, 2020 and August 18, 2020, inclusive (the Class Period).   GlobeNewswire Inc
Oct 26, 2020
05:26PM EDT  Hagens Berman updates investors in the following publicly-traded companies and urges investors who have suffered significant losses to contact the firm. Further details about the cases can be found at the links provided.   GlobeNewswire Inc
12:30PM EDT  Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.   GlobeNewswire Inc
Oct 25, 2020
12:42PM EDT  ROSEN, TRUSTED INVESTOR COUNSEL, Reminds BioMarin Pharmaceutical   GlobeNewswire Inc
Oct 23, 2020
10:50PM EDT  ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits:   GlobeNewswire Inc
12:00PM EDT  Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class   PR Newswire
Oct 22, 2020
12:00PM EDT  The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.   GlobeNewswire Inc
08:31AM EDT  BioMarin to Host Third Quarter 2020 Financial Results Conference Call and   PR Newswire


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC